MiMedx Group, Inc.

MDXG

US6024961012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
6.79 ^USD	-0.44%		-2.02%	-22.58%

Jul. 02	Cantor Fitzgerald Initiates MiMedx at Overweight Rating With $11 Price Target	MT
Jul. 01	MiMedx Group, Inc.(NasdaqCM:MDXG) added to Russell 3000 Growth Index	CI

MiMedx Group, Inc. Reports Consolidated Impairment for the First Quarter Ended March 31, 2024

April 30, 2024 at 04:10 pm EDT

MiMedx Group, Inc. reported consolidated impairment for the first quarter ended March 31, 2024. For the quarter, the company reported impairment of intangible assets of $54,000.

Latest news about MiMedx Group, Inc.

Cantor Fitzgerald Initiates MiMedx at Overweight Rating With $11 Price Target	Jul. 02	MT
MiMedx Group, Inc.(NasdaqCM:MDXG) added to Russell 3000 Growth Index	Jun. 30	CI
MiMedx Group, Inc.(NasdaqCM:MDXG) added to Russell Microcap Growth Index	Jun. 30	CI
MiMedx Group, Inc.(NasdaqCM:MDXG) added to Russell 3000E Growth Index	Jun. 30	CI
MiMedx Group, Inc.(NasdaqCM:MDXG) added to Russell 2000 Growth Index	Jun. 30	CI
MiMedx Group, Inc.(NasdaqCM:MDXG) added to Russell 2500 Growth Index	Jun. 30	CI
MiMedx Group, Inc.(NasdaqCM:MDXG) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
MiMedx Group Promotes Kim Moller to Chief Commercial Officer	Jun. 26	MT
MiMedx Group, Inc. Announces the Appointment of Kim Moller to Chief Commercial Officer	Jun. 26	CI
Transcript : MiMedx Group, Inc., Q1 2024 Earnings Call, Apr 30, 2024	Apr. 30
Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 Revenue $84.7M, vs. Street Est of $79.4M	Apr. 30	MT
Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 EPS $0.07, vs. Street Est of $0.04	Apr. 30	MT
MiMedx Group, Inc. Reports Consolidated Impairment for the First Quarter Ended March 31, 2024	Apr. 30	CI
MiMedx Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30	CI
MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products	Mar. 27	MT
MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit	Mar. 27	DJ
MiMedx Group, Inc. Provides Update on AXIOFILL Request for Designation from FDA	Mar. 27	CI
MiMedx Group to Buy Distribution Rights for TELA Bio's Wound Care Product	Mar. 20	MT
MiMedx Launches E-Commerce Platform	Mar. 13	MT
Mimedx Introduces E-Commerce and Account Management Platform	Mar. 13	CI
Lake Street Starts MiMedx Group With Buy Rating, $12 Price Target	Mar. 07	MT
MiMedx Group, Inc. Announces Appointment of New Independent Directors	Mar. 04	CI
Mizuho Securities Raises Price Target on MiMedx to $14 From $13, Maintains Buy Rating	Mar. 01	MT
Spectral AI Names Peter Carlson Chief Executive Officer; Reaffirms 2024 Preliminary Revenue Guidance	Mar. 01	MT
Transcript : MiMedx Group, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28

MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.

Sector

Biotechnology & Medical Research

Calendar

2024-07-29 - Q2 2024 Earnings Release (Projected)

More about the company